High Costs & Systemic Barriers Exacerbate Health Inequities Policy Reforms Are Critical to Address Structural Inequities High Costs and Systemic Barriers Exacerbate Health Inequities: The products Ozempic, Rybelsus, and Wegovy (semaglutide) and Mounjaro and Zepbound (tirzepatide) are priced at roughly $1,000 per month
It may also support healthy aging and cardiovascular health
While cost and insurance coverage remain the leading reasons why consumers have stopped taking a GLP-1 medication, that percentage is down from early April data
Qian MB, Chen YD, Fang YY, Xu LQ, Zhu TJ, Tan T, Zhou CH, Wang GF, Jia TW, Yang GJ, Zhou XN
Instantly gain access to our library of assets, product guides, and digital and print media to help you create great content